Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine

Saraceno, Janaína Jamile Ferreira; Souza, Guilherme Macedo; Finamor, Luciana Peixoto dos Santos; Nascimento, Heloisa; Belfort, Rubens

doi:10.1186/s40942-021-00319-3

Cited by 54 publications

(51 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ocular inflammatory events after COVID-19 vaccination from a multinational case series are described in this study. A search of Medline, using PubMed and Google Scholar, performed in August 2021, using the following keywords: ‘uveitis’, ‘vaccination’, ‘COVID-19’, revealed six case reports and two national case series describing presumed COVID-19 vaccine-related uveitis have been reported so far, including new onset of bilateral juvenile idiopathic arthritis (JIA)-associated anterior uveitis, unilateral anterior uveitis, bilateral choroiditis complicated by subretinal fluid, bilateral panuveitis with choroidal thickening and vascular leakage, and recurrence of Vogt Koyanagi Harada (VKH) [ 19 – 26 ]. Rabinovitch et al reported twenty one cases of uveitis after COVID-19 vaccination in Israel, of which nineteen were diagnosed with anterior uveitis and two developed multiple evanescent white dot syndrome (MEWDS) [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Ocular inflammatory events following COVID-19 vaccination: a multinational case series

Brandão-de-Resende

Steeples²,

Balasubramaniam³

et al. 2022

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

Background Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Ocular inflammatory events following COVID-19 vaccination: a multinational case series

Brandão-de-Resende

Steeples²,

Balasubramaniam³

et al. 2022

J Ophthal Inflamm Infect

View full text Add to dashboard Cite

show abstract

“…At a three week follow up, the patient remarkably demonstrated visual acuity of 20/20 in both eyes with no signs of inflammatory activity and resolution of the exudative retinal detachments. Of note, the authors also described a case of VKH which developed in a 37-year-old female patient two weeks after she tested positive for COVID-19 on a polymerase chain reaction (PCR) test-i.e., in the setting of COVID-19 infection-as opposed to after vaccination [51]. Similarly, the patient had vision loss and signs of inflammation: She had KPs OD, mild vitritis bilaterally, and fluorescein angiography demonstrated bilateral optic disc hyperfluorescence due to leakage.…”

Section: Vogt-koyanagi-harada Diseasementioning

confidence: 97%

“…In another report, Saraceno et al described a 62-year-old female who developed acute bilateral loss of vision two days after receiving the AZD1222 vaccine [51]. She was found to have visual acuity of 20/600 OD and 20/200 OS.…”

Section: Vogt-koyanagi-harada Diseasementioning

confidence: 99%

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

et al. 2022

View full text Add to dashboard Cite

Vaccination efforts as a mitigation strategy in the corona virus disease 2019 (COVID-19) pandemic are fully underway. A vital component of understanding the optimal clinical use of these vaccines is a thorough investigation of adverse events following vaccination. To date, some limited reports and reviews have discussed ocular adverse events following COVID-19 vaccination, but a systematic review detailing these reports with manifestations and clinical courses as well as proposed mechanisms has yet to be published. This comprehensive review one-year into vaccination efforts against COVID-19 is meant to furnish sound understanding for ophthalmologists and primary care physicians based on the existing body of clinical data. We discuss manifestations categorized into one of the following: eyelid, orbit, uveitis, retina, vascular, neuro-ophthalmology, ocular motility disorders, and other.

show abstract

“…The retina and the uvea are the most commonly involved ocular structures following COVID-19 vaccination with 50 cases reported in the literature, 21 being contributed by a retrospective study from Israel [ Table 3 ]. [ 16 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 ] The mean age was 43.6 ± 17.2 (median 40) years with 23 males and 23 females (unspecified in 4). The symptoms developed at a median interval of 4 (mean 7.4 ± 8.5 ) days from the time of vaccination.…”

Section: Posterior Segment Manifestations Of Covid-19 Vaccinementioning

confidence: 99%

“…Viral infections have been known to trigger VKH with cytomegalovirus (CMV), influenza A, hepatitis C being implicated. [ 18 ] Antigenic cross-reactivity, HLA-DR4 status of patient (with influenza A), and interferon have been the mechanisms suggested in relation to viral infections causing VKH. Bacillus Calmette-Guerin (BCG) vaccine, influenza, hepatitis B, and yellow fever vaccinations have all been reported to cause cases of VKH, the onset ranging from 3 days to 4 weeks.…”

Section: Posterior Segment Manifestations Of Covid-19 Vaccinementioning

confidence: 99%

After the Storm: Ophthalmic Manifestations of COVID-19 Vaccines

Sen

Honavar

2021

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Several COVID-19 vaccines have been developed and approved for use around the world from December 2020, to combat the pandemic caused by the novel SARS-CoV-2 virus. Several ophthalmic manifestations of the COVID-19 vaccines have been reported by ophthalmologists. This review was undertaken to recognize, encourage active reporting and determine the pathogenesis and time of appearance for better awareness and understanding of the ophthalmic manifestations of COVID-19 vaccines. A literature search was performed for publications on the ophthalmic manifestations of COVID-19 vaccines between January 1, 2021 and November 7, 2021. 23 case reports, 17 letters to editors, 3 ophthalmic images, 4 brief communications, 4 retrospective cohort studies and 2 case control studies were included. Posterior segment, including the uvea, choroid and retinal vasculature, was most commonly affected and the reported clinical features developed at a median of four days from the time of vaccination. The possible mechanisms include molecular mimicry of the vaccine components with host ocular tissues, antigen-specific cell and antibody-mediated hypersensitivity reactions to viral antigens and adjuvants present in the vaccines. The causal relationship of the ocular signs and symptoms and COVID-19 vaccines has not been established and requires long-term and large multicentre data. Most of the reported manifestations are mild, transient and adequately treated when diagnosed and managed early. The benefits of COVID-19 vaccination outweighs the reported rare adverse events and should not be a deterrent to vaccination.

show abstract

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine

Cited by 54 publications

References 22 publications

Ocular inflammatory events following COVID-19 vaccination: a multinational case series

Ocular inflammatory events following COVID-19 vaccination: a multinational case series

Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective

After the Storm: Ophthalmic Manifestations of COVID-19 Vaccines

Contact Info

Product

Resources

About